Table 2.
Protein dose-escalation ex vivo biodistribution of 89Zr-DFO-trastuzumab
| Organs (%ID/g) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Blood | Bone | Heart | Kidneys | Liver | Lungs | Muscle | Spleen | Tumor | |
| Random | 2.13 ± 0.3 | 2.82 ± 0.2 | 0.84 ± 0.1 | 1.55 ± 0.1 | 3.24 ± 0.2 | 1.34 ± 0.1 | 0.4 ± 0.1 | 2.08 ± 0.2 | 10.9 ± 1.3 |
| Random+100 µg | 1.66 ± 0.3 | 2.71 ± 0.2 | 0.97 ± 0.1 | 1.81 ± 0.2 | 3.22 ± 0.2 | 1.21 ± 0.1 | 0.54 ± 0.1 | 4.56 ± 0.6 | 10.4 ± 0.8 |
| Random+500 µg | 3.13 ± 0.5 | 2.58 ± 0.2 | 1.17 ± 0.1 | 1.88 ± 0.1 | 2.54 ± 0.2 | 1.97 ± 0.2 | 0.43 ± 0.1 | 2.83 ± 0.6 | 9.9 ± 1.0 |
| β-Gal | 3.90 ± 1.4 | 2.45 ± 0.5 | 1.34 ± 0.2 | 2.12 ± 0.2 | 7.11 ± 1.8 | 1.81 ± 0.3 | 0.89 ± 0.2 | 5.44 ± 2.7 | 24.1 ± 4.3 |
| β-Gal+100 µg | 3.8 ± 1.1 | 2.26 ± 0.1 | 1.49 ± 0.2 | 2.02 ± 0.2 | 4.5 ± 0.2 | 2.16 ± 0.5 | 0.78 ± 0.1 | 4.3 ± 0.8 | 25.2 ± 1.6 |
| β-Gal+500 µg | 6.58 ± 1.1 | 1.92 ± 0.6 | 2.14 ± 0.2 | 2.34 ± 0.2 | 3.42 ± 0.2 | 2.86 ± 0.4 | 0.81 ± 0.2 | 4.66 ± 0.6 | 24.4 ± 1.9 |
| EndoS2 | 5.8 ± 0.6 | 2.71 ± 0.3 | 1.63 ± 0.1 | 2.23 ± 0.2 | 4.64 ± 0.4 | 2.6 ± 0.4 | 0.66 ± 0.1 | 3.43 ± 0.1 | 30.7 ± 3.1 |
| EndoS2+100 µg | 5.42 ± 1.1 | 2.32 ± 0.4 | 1.93 ± 0.1 | 2.57 ± 0.3 | 2.77 ± 0.2 | 2.8 ± 0.4 | 1.0 ± 0.3 | 2.93 ± 0.5 | 28.3 ± 2.9 |
| EndoS2+500 µg | 6.1 ± 0.2 | 2.7 ± 0.1 | 2.14 ± 0.1 | 2.86 ± 0.2 | 3.1 ± 0.5 | 3.42 ± 0.2 | 1.0 ± 0.2 | 8.14 ± 2.0 | 24.4 ± 1.9 |
Values are mean ± SEM